PETROSCRAPS.COM

PolyMedix Receives Phase 2 NIH Grant to Develop a Novel Antimicrobial Defensin Mimetic for Oral Candidiasis RADNOR, Pa.—-PolyMedix, Inc. , an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. Read more on Business Wire via Yahoo!…. Click Here to Read More

Rodman & Renshaw Announces Analyst Discussion with PolyMedix, Inc. NEW YORK—-Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. , a leading full service investment bank for growth companies today announced that on August 4, 2010, Rodman will host an analyst discussion in its media center with Nicholas Landekic, President and Chief Executive Officer, and Bozena Korczak, Ph.D., Vice President, Drug Development, of PolyMedix, Inc. Read more on Business Wire via Yahoo!…. Click Here to Read More

PolyMedix to Review Results from Recent Phase 1B LMWH Reversal Clinical Study with Heptagonist PMX-60056 RADNOR, Pa.—-PolyMedix, Inc. , an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has scheduled a webcast for Wednesday, June 9 at 4:00 PM Eastern Time. Read more on Business Wire via Yahoo!…. Click Here to Read More